MONTREAL — Innospera Pharma has named Dr. Glenn Crater, MD, FCCP, as its new Chief Medical Officer, the company announced Wednesday. Dr. Crater will initially serve in a fractional capacity before transitioning to a full-time role as the company’s lead therapeutic candidate, ING-006, enters clinical development.
Innospera is developing small molecule modulators targeting GPR84 and GPR40 receptors to treat inflammatory and metabolic diseases. Its lead compound, ING-006, is being developed for idiopathic pulmonary fibrosis (IPF), a serious and progressive lung condition with limited treatment options.
Dr. Crater, a board-certified pulmonologist, brings more than 25 years of clinical, regulatory, and leadership experience in respiratory drug development. He has previously served as Chief Medical Officer at multiple biotechnology companies and has contributed to successful regulatory submissions and clinical programs targeting fibrotic and respiratory diseases.
“We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,” said François Ravenelle, PhD, CEO of Innospera. “Having worked closely with Glenn at Inversago Pharma, I’ve seen his deep commitment to scientific rigor and patient-focused innovation. His expertise in IPF will be instrumental as we initiate clinical studies for ING-006.”
Dr. Crater said he was excited to join Innospera and reunite with Ravenelle. “ING-006 represents a promising new approach to modulating inflammation and fibrosis through GPCR lipid signaling,” he said. “I look forward to helping advance this program and bring potential new therapies to patients with IPF and related conditions.”
The appointment marks a strategic step forward for Innospera as it moves closer to clinical-stage development and expands its pipeline of GPR84 and GPR40-targeting therapeutics.
